



National Institute of Public Health of Quebec

[Français](#)

[Español](#)

[Welcome](#)  
[Jobs](#)

# INSPQ

## Center of Expertise and Reference in Public Health

[To research](#)


The Institute | Expertise | Training | Our productions

1. [Welcome](#)
2. > [Our products](#)
3. > [Publications](#)

### Use of Medicago's Covifenz recombinant protein vaccine against COVID-19

[Read the document](#)

- Covifenz is a recombinant protein vaccine against COVID-19 with adjuvant from the company Medicago.
- A randomized clinical trial concluded that a primary series of two doses of the Covifenz vaccine against the Delta and Gamma variants was effective. We have no data on its effectiveness against the Omicron variant, either when given to people aged 65 and over or when given as a booster dose (third dose).
- Covifenz is based on classic technology, which could improve the acceptability of a vaccination for people who have a real fear of vaccines based on newer technologies such as messenger RNA (mRNA).
- The accumulated experience with mRNA vaccines is greater than with recombinant protein vaccines against COVID-19 (Nuvaxovid and Covifenz) and their efficacy appears slightly higher. For this reason, it is preferable to use mRNA vaccines for primary immunization and booster doses in most situations.
- The CIQ recommends the use of the Covifenz vaccine in the primary series for people aged 18 to 64 who have a contraindication to the administration of an mRNA vaccine or who would refuse this latter type of vaccine.
- The CIQ recommends an interval of 8 weeks between the 2 scheduled doses.



- Author(s):**
- [Nicholas Brousseau](#)
  - [Yen Giang Bui](#)
  - [Philippe De Wals](#)
- Committee:**
- [Quebec Immunization Committee](#)
- Topics):**
- [Immunization](#)
  - [COVID-19](#)
- Post type:**
- [Interim document](#)

April 19, 2022

**Publication date:**

- [The Institute](#)
- [Quebec Public Health Laboratory](#)
- [Quebec Toxicology Center](#)
- [Documentation centers](#)
- [Contact U.S.](#)
- [Jobs](#)
- [Sitemap](#)
- [Privacy Policy](#)
- [Accessibility](#)

### Expertise

- [Development of people and communities](#)
- [Analyzes of the health status of the population](#)
- [Lifestyle habits and chronic disease prevention](#)
- [Specialized laboratories and screening](#)
- [Infectious diseases](#)
- [Health at work](#)
- [Indigenous health](#)
- [Environmental Health and Toxicology](#)
- [Safety, violence and injury prevention](#)

Les Résonances  
The newsletter  
of the Institute

[Subscribe here](#)  
[Latest issues](#)

Follow us on :



[Mobile version](#)

